ID   AXIN1_HUMAN             Reviewed;         862 AA.
AC   O15169; Q4TT26; Q4TT27; Q86YA7; Q8WVW6; Q96S28;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2002, sequence version 2.
DT   18-JUN-2025, entry version 247.
DE   RecName: Full=Axin-1;
DE   AltName: Full=Axis inhibition protein 1;
DE            Short=hAxin;
GN   Name=AXIN1; Synonyms=AXIN;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9230313; DOI=10.1016/s0092-8674(00)80324-4;
RA   Zeng L., Fagotto F., Zhang T., Hsu W., Vasicek T.J., Perry W.L. III,
RA   Lee J.J., Tilghman S.M., Gumbiner B.M., Costantini F.;
RT   "The mouse Fused locus encodes Axin, an inhibitor of the Wnt signaling
RT   pathway that regulates embryonic axis formation.";
RL   Cell 90:181-192(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11157797; DOI=10.1093/hmg/10.4.339;
RA   Daniels R.J., Peden J.F., Lloyd C., Horsley S.W., Clark K., Tufarelli C.,
RA   Kearney L., Buckle V.J., Doggett N.A., Flint J., Higgs D.R.;
RT   "Sequence, structure and pathology of the fully annotated terminal 2 Mb of
RT   the short arm of human chromosome 16.";
RL   Hum. Mol. Genet. 10:339-352(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X., Xie G.,
RA   Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A., Bajorek E.,
RA   Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J., Buckingham J.M.,
RA   Callen D.F., Campbell C.S., Campbell M.L., Campbell E.W., Caoile C.,
RA   Challacombe J.F., Chasteen L.A., Chertkov O., Chi H.C., Christensen M.,
RA   Clark L.M., Cohn J.D., Denys M., Detter J.C., Dickson M.,
RA   Dimitrijevic-Bussod M., Escobar J., Fawcett J.J., Flowers D., Fotopulos D.,
RA   Glavina T., Gomez M., Gonzales E., Goodstein D., Goodwin L.A., Grady D.L.,
RA   Grigoriev I., Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E.,
RA   Huang W., Israni S., Jett J., Jewett P.B., Kadner K., Kimball H.,
RA   Kobayashi A., Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y.,
RA   Lowry S., Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L., Rash S.,
RA   Retterer J., Ricke D.O., Robinson D.L., Rodriguez A., Salamov A.,
RA   Saunders E.H., Scott D., Shough T., Stallings R.L., Stalvey M.,
RA   Sutherland R.D., Tapia R., Tesmer J.G., Thayer N., Thompson L.S., Tice H.,
RA   Torney D.C., Tran-Gyamfi M., Tsai M., Ulanovsky L.E., Ustaszewska A.,
RA   Vo N., White P.S., Williams A.L., Wills P.L., Wu J.-R., Wu K., Yang J.,
RA   DeJong P., Bruce D., Doggett N.A., Deaven L., Schmutz J., Grimwood J.,
RA   Richardson P., Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M.,
RA   Myers R.M., Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 471-862 (ISOFORM 1).
RC   TISSUE=Lymphoma, and Renal cell carcinoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH GSK3B AND PPP2CA, PHOSPHORYLATION, AND DEPHOSPHORYLATION.
RX   PubMed=9920888; DOI=10.1074/jbc.274.6.3439;
RA   Hsu W., Zeng L., Costantini F.;
RT   "Identification of a domain of Axin that binds to the serine/threonine
RT   protein phosphatase 2A and a self-binding domain.";
RL   J. Biol. Chem. 274:3439-3445(1999).
RN   [6]
RP   DISEASE.
RX   PubMed=10700176; DOI=10.1038/73448;
RA   Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T.,
RA   Kawasoe T., Ishiguro H., Fujita M., Tokino T., Sasaki Y., Imaoka S.,
RA   Murata M., Shimano T., Yamaoka Y., Nakamura Y.;
RT   "AXIN1 mutations in hepatocellular carcinomas, and growth suppression in
RT   cancer cells by virus-mediated transfer of AXIN1.";
RL   Nat. Genet. 24:245-250(2000).
RN   [7]
RP   INTERACTION WITH LRP5.
RX   PubMed=11336703; DOI=10.1016/s1097-2765(01)00224-6;
RA   Mao J., Wang J., Liu B., Pan W., Farr G.H. III, Flynn C., Yuan H.,
RA   Takada S., Kimelman D., Li L., Wu D.;
RT   "Low-density lipoprotein receptor-related protein-5 binds to Axin and
RT   regulates the canonical Wnt signaling pathway.";
RL   Mol. Cell 7:801-809(2001).
RN   [8]
RP   INTERACTION WITH MDFI AND MDFIC, AND FUNCTION.
RX   PubMed=12192039; DOI=10.1128/mcb.22.18.6393-6405.2002;
RA   Kusano S., Raab-Traub N.;
RT   "I-mfa domain proteins interact with Axin and affect its regulation of the
RT   Wnt and c-Jun N-terminal kinase signaling pathways.";
RL   Mol. Cell. Biol. 22:6393-6405(2002).
RN   [9]
RP   INTERACTION WITH DAB2.
RX   PubMed=12805222; DOI=10.1093/emboj/cdg286;
RA   Howe P.H.;
RT   "Regulation of the Wnt signaling pathway by disabled-2 (Dab2).";
RL   EMBO J. 22:3084-3094(2003).
RN   [10]
RP   INTERACTION WITH DIXDC1; MAP3K1 AND MAP3K4.
RX   PubMed=15262978; DOI=10.1074/jbc.m404598200;
RA   Wong C.K., Luo W., Deng Y., Zou H., Ye Z., Lin S.-C.;
RT   "The DIX domain protein coiled-coil-DIX1 inhibits c-Jun N-terminal kinase
RT   activation by Axin and dishevelled through distinct mechanisms.";
RL   J. Biol. Chem. 279:39366-39373(2004).
RN   [11]
RP   INVOLVEMENT IN CAUDAL DUPLICATION ANOMALY.
RX   PubMed=16773576; DOI=10.1086/505031;
RA   Oates N.A., van Vliet J., Duffy D.L., Kroes H.Y., Martin N.G.,
RA   Boomsma D.I., Campbell M., Coulthard M.G., Whitelaw E., Chong S.;
RT   "Increased DNA methylation at the AXIN1 gene in a monozygotic twin from a
RT   pair discordant for a caudal duplication anomaly.";
RL   Am. J. Hum. Genet. 79:155-162(2006).
RN   [12]
RP   INTERACTION WITH SMAD6; SMAD7 AND RNF111, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16601693; DOI=10.1038/sj.emboj.7601057;
RA   Liu W., Rui H., Wang J., Lin S., He Y., Chen M., Li Q., Ye Z., Zhang S.,
RA   Chan S.C., Chen Y.-G., Han J., Lin S.-C.;
RT   "Axin is a scaffold protein in TGF-beta signaling that promotes degradation
RT   of Smad7 by Arkadia.";
RL   EMBO J. 25:1646-1658(2006).
RN   [13]
RP   INTERACTION WITH DAXX, IDENTIFICATION AS A COMPONENT OF THE
RP   AXIN1-HIPK2-TP53 COMPLEX, SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=17210684; DOI=10.1158/0008-5472.can-06-1671;
RA   Li Q., Wang X., Wu X., Rui Y., Liu W., Wang J., Wang X., Liou Y.C., Ye Z.,
RA   Lin S.C.;
RT   "Daxx cooperates with the Axin/HIPK2/p53 complex to induce cell death.";
RL   Cancer Res. 67:66-74(2007).
RN   [14]
RP   PHOSPHORYLATION AT SER-75; SER-77; SER-217 AND SER-469, INTERACTION WITH
RP   GSK3B AND PPP1CA, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=17318175; DOI=10.1038/sj.emboj.7601607;
RA   Luo W., Peterson A., Garcia B.A., Coombs G., Kofahl B., Heinrich R.,
RA   Shabanowitz J., Hunt D.F., Yost H.J., Virshup D.M.;
RT   "Protein phosphatase 1 regulates assembly and function of the beta-catenin
RT   degradation complex.";
RL   EMBO J. 26:1511-1521(2007).
RN   [15]
RP   SUMOYLATION.
RX   PubMed=18632848; DOI=10.1096/fj.08-113910;
RA   Kim M.J., Chia I.V., Costantini F.;
RT   "SUMOylation target sites at the C terminus protect Axin from
RT   ubiquitination and confer protein stability.";
RL   FASEB J. 22:3785-3794(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   ADP-RIBOSYLATION, UBIQUITINATION, DOMAIN TANKYRASE-BINDING MOTIF, AND
RP   INTERACTION WITH TNKS AND TNKS2.
RX   PubMed=19759537; DOI=10.1038/nature08356;
RA   Huang S.M., Mishina Y.M., Liu S., Cheung A., Stegmeier F., Michaud G.A.,
RA   Charlat O., Wiellette E., Zhang Y., Wiessner S., Hild M., Shi X.,
RA   Wilson C.J., Mickanin C., Myer V., Fazal A., Tomlinson R., Serluca F.,
RA   Shao W., Cheng H., Shultz M., Rau C., Schirle M., Schlegl J., Ghidelli S.,
RA   Fawell S., Lu C., Curtis D., Kirschner M.W., Lengauer C., Finan P.M.,
RA   Tallarico J.A., Bouwmeester T., Porter J.A., Bauer A., Cong F.;
RT   "Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling.";
RL   Nature 461:614-620(2009).
RN   [18]
RP   UBIQUITINATION, DEUBIQUITINATION BY USP34, AND SUBCELLULAR LOCATION.
RX   PubMed=21383061; DOI=10.1128/mcb.01094-10;
RA   Lui T.T., Lacroix C., Ahmed S.M., Goldenberg S.J., Leach C.A., Daulat A.M.,
RA   Angers S.;
RT   "The Ubiquitin specific protease USP34 regulates Axin stability and
RT   Wnt/beta-catenin signaling.";
RL   Mol. Cell. Biol. 31:2053-2065(2011).
RN   [19]
RP   ADP-RIBOSYLATION, UBIQUITINATION, AND INTERACTION WITH RNF146; TNKS AND
RP   TNKS2.
RX   PubMed=21478859; DOI=10.1038/ncb2222;
RA   Zhang Y., Liu S., Mickanin C., Feng Y., Charlat O., Michaud G.A.,
RA   Schirle M., Shi X., Hild M., Bauer A., Myer V.E., Finan P.M., Porter J.A.,
RA   Huang S.M., Cong F.;
RT   "RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin
RT   degradation and Wnt signalling.";
RL   Nat. Cell Biol. 13:623-629(2011).
RN   [20]
RP   INTERACTION WITH TNKS, AND UBIQUITINATION.
RX   PubMed=21799911; DOI=10.1371/journal.pone.0022595;
RA   Callow M.G., Tran H., Phu L., Lau T., Lee J., Sandoval W.N., Liu P.S.,
RA   Bheddah S., Tao J., Lill J.R., Hongo J.A., Davis D., Kirkpatrick D.S.,
RA   Polakis P., Costa M.;
RT   "Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt
RT   signaling.";
RL   PLoS ONE 6:E22595-E22595(2011).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-77; SER-486; SER-511 AND
RP   SER-581, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [23]
RP   INTERACTION WITH WDR26, AND FUNCTION.
RX   PubMed=27098453; DOI=10.1002/1873-3468.12180;
RA   Goto T., Matsuzawa J., Iemura S., Natsume T., Shibuya H.;
RT   "WDR26 is a new partner of Axin1 in the canonical Wnt signaling pathway.";
RL   FEBS Lett. 590:1291-1303(2016).
RN   [24]
RP   INTERACTION WITH GID8; GSK3B AND CTNNB1.
RX   PubMed=28829046; DOI=10.1038/cr.2017.107;
RA   Lu Y., Xie S., Zhang W., Zhang C., Gao C., Sun Q., Cai Y., Xu Z., Xiao M.,
RA   Xu Y., Huang X., Wu X., Liu W., Wang F., Kang Y., Zhou T.;
RT   "Twa1/Gid8 is a beta-catenin nuclear retention factor in Wnt signaling and
RT   colorectal tumorigenesis.";
RL   Cell Res. 27:1422-1440(2017).
RN   [25]
RP   FUNCTION, INTERACTION WITH GSK3B; SIAH1 AND SIAH2, UBIQUITINATION, AND
RP   MUTAGENESIS OF VAL-383 AND PRO-385.
RX   PubMed=28546513; DOI=10.1101/gad.300053.117;
RA   Ji L., Jiang B., Jiang X., Charlat O., Chen A., Mickanin C., Bauer A.,
RA   Xu W., Yan X., Cong F.;
RT   "The SIAH E3 ubiquitin ligases promote Wnt/beta-catenin signaling through
RT   mediating Wnt-induced Axin degradation.";
RL   Genes Dev. 31:904-915(2017).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.57 ANGSTROMS) OF 74-220 IN COMPLEX WITH APC.
RX   PubMed=10811618; DOI=10.1093/emboj/19.10.2270;
RA   Spink K.E., Polakis P., Weis W.I.;
RT   "Structural basis of the axin-adenomatous polyposis coli interaction.";
RL   EMBO J. 19:2270-2279(2000).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 383-400 IN COMPLEX WITH GSK3B.
RX   PubMed=12554650; DOI=10.1093/emboj/cdg068;
RA   Dajani R., Fraser E., Roe S.M., Yeo M., Good V.M., Thompson V., Dale T.C.,
RA   Pearl L.H.;
RT   "Structural basis for recruitment of glycogen synthase kinase 3beta to the
RT   axin-APC scaffold complex.";
RL   EMBO J. 22:494-501(2003).
RN   [28]
RP   INVOLVEMENT IN HCC, VARIANTS HCC ARG-106; LEU-345 AND SER-425, AND VARIANTS
RP   SER-650 AND GLN-841.
RX   PubMed=12101426; DOI=10.1038/sj.onc.1205591;
RA   Taniguchi K., Roberts L.R., Aderca I.N., Dong X., Qian C., Murphy L.M.,
RA   Nagorney D.M., Burgart L.J., Roche P.C., Smith D.I., Ross J.A., Liu W.;
RT   "Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular
RT   carcinomas and hepatoblastomas.";
RL   Oncogene 21:4863-4871(2002).
RN   [29]
RP   VARIANTS CMDOH 723-ARG--ASP-862 DEL AND 841-ARG--ASP-862 DEL,
RP   CHARACTERIZATION OF VARIANT CMDOH 723-ARG--ASP-862 DEL, AND INVOLVEMENT IN
RP   CMDOH.
RX   PubMed=37582359; DOI=10.1016/j.ajhg.2023.07.011;
RA   Terhal P., Venhuizen A.J., Lessel D., Tan W.H., Alswaid A., Gruen R.,
RA   Alzaidan H.I., von Kroge S., Ragab N., Hempel M., Kubisch C., Novais E.,
RA   Cristobal A., Tripolszki K., Bauer P., Fischer-Zirnsak B.,
RA   Nievelstein R.A.J., van Dijk A., Nikkels P., Oheim R., Hahn H.,
RA   Bertoli-Avella A., Maurice M.M., Kornak U.;
RT   "AXIN1 bi-allelic variants disrupting the C-terminal DIX domain cause
RT   craniometadiaphyseal osteosclerosis with hip dysplasia.";
RL   Am. J. Hum. Genet. 110:1470-1481(2023).
CC   -!- FUNCTION: Component of the beta-catenin destruction complex required
CC       for regulating CTNNB1 levels through phosphorylation and
CC       ubiquitination, and modulating Wnt-signaling (PubMed:12192039,
CC       PubMed:27098453, PubMed:28829046). Controls dorsoventral patterning via
CC       two opposing effects; down-regulates CTNNB1 to inhibit the Wnt
CC       signaling pathway and ventralize embryos, but also dorsalizes embryos
CC       by activating a Wnt-independent JNK signaling pathway
CC       (PubMed:12192039). In Wnt signaling, probably facilitates the
CC       phosphorylation of CTNNB1 and APC by GSK3B (PubMed:12192039). Likely to
CC       function as a tumor suppressor. Enhances TGF-beta signaling by
CC       recruiting the RNF111 E3 ubiquitin ligase and promoting the degradation
CC       of inhibitory SMAD7 (PubMed:16601693). Also a component of the AXIN1-
CC       HIPK2-TP53 complex which controls cell growth, apoptosis and
CC       development (PubMed:17210684). Facilitates the phosphorylation of TP53
CC       by HIPK2 upon ultraviolet irradiation (PubMed:17210684).
CC       {ECO:0000269|PubMed:12192039, ECO:0000269|PubMed:16601693,
CC       ECO:0000269|PubMed:17210684, ECO:0000269|PubMed:27098453,
CC       ECO:0000269|PubMed:28546513}.
CC   -!- SUBUNIT: Homodimer (By similarity). Interacts with ZBED3; the
CC       interaction is direct, enhanced by protein kinase GSK3B and casein
CC       kinase CSNK1E activities and decreases GSK3B-induced beta-catenin
CC       serine and threonine phosphorylations (By similarity). Component of the
CC       beta-catenin destruction complex, containing at least, CTNNB1, an axin
CC       and GSK3B, that regulates CTNNB1 protein levels through phosphorylation
CC       and ubiquitination. Interacts with CTNNB1 (via the armadillo repeats 2-
CC       7). Interacts with GSK3B; the interaction hyperphosphorylates CTNNB1
CC       leading to its ubiquitination and destruction (PubMed:12554650,
CC       PubMed:17318175, PubMed:28546513). Component of the AXIN1-HIPK2-TP53
CC       complex (PubMed:17210684). Interacts directly in the complex with TP53
CC       and HIPK2 (PubMed:17210684). Interacts with DAXX; the interaction
CC       stimulates the interaction of DAXX with TP53, stimulates 'Ser-46'
CC       phosphorylation of TP53 and induces cell death on UV irradiation
CC       (PubMed:17210684). Also binds APC, SMAD6, SMAD7 and RNF111
CC       (PubMed:10811618, PubMed:16601693). Interacts with DIXDC1; prevents
CC       interaction with MAP3K1 (PubMed:15262978). Interacts with MAP3K4
CC       (PubMed:15262978). Interacts with ANKRD6 and AIDA (By similarity).
CC       Interacts with MDFI; the interaction decreases AXIN1-mediated JUN N-
CC       terminal kinase (JNK) activation (PubMed:12192039). Interacts with
CC       MDFIC; the interaction inhibits beta-cateninin-mediated signaling and
CC       AXIN1-mediated JUN N-terminal kinase (JNK) activation
CC       (PubMed:12192039). Interacts with LRP5 (via its phosphorylated PPPSP
CC       motifs); the interaction is stimulated by WNT1 and GSK3B and activates
CC       beta-catenin signaling (PubMed:11336703). Interacts (via the C-
CC       terminal) with PPP1CA; the interaction dephosphorylates AXIN1 and
CC       regulates interaction with GSK3B (PubMed:9920888). Interacts with
CC       PPP2CA; the interaction dephosphorylates AXIN1 (PubMed:9920888).
CC       Interacts with MACF1 (By similarity). Found in a complex composed of
CC       MACF1, APC, AXIN1, CTNNB1 and GSK3B (By similarity). Interacts with
CC       TNKS (PubMed:19759537, PubMed:21478859, PubMed:21799911). Interacts
CC       with DAB2; the interaction is mutually exclusive with the AXIN1:PPP1CA
CC       interaction (PubMed:12805222). Interacts with WDR26 (PubMed:27098453).
CC       Interacts with GID8 (PubMed:28829046). Interacts with SIAH1 and SIAH2;
CC       both probably catalyze AXIN1 ubiquitination and subsequent proteasome-
CC       mediated ubiquitin-dependent degradation (PubMed:28546513). Interaction
CC       with GSK3B and AXIN1 is competitive (PubMed:28546513).
CC       {ECO:0000250|UniProtKB:O35625, ECO:0000250|UniProtKB:O70239,
CC       ECO:0000269|PubMed:10811618, ECO:0000269|PubMed:11336703,
CC       ECO:0000269|PubMed:12192039, ECO:0000269|PubMed:12554650,
CC       ECO:0000269|PubMed:12805222, ECO:0000269|PubMed:15262978,
CC       ECO:0000269|PubMed:16601693, ECO:0000269|PubMed:17210684,
CC       ECO:0000269|PubMed:17318175, ECO:0000269|PubMed:19759537,
CC       ECO:0000269|PubMed:21478859, ECO:0000269|PubMed:21799911,
CC       ECO:0000269|PubMed:27098453, ECO:0000269|PubMed:28546513,
CC       ECO:0000269|PubMed:28829046, ECO:0000269|PubMed:9920888}.
CC   -!- INTERACTION:
CC       O15169; Q5JTC6: AMER1; NbExp=7; IntAct=EBI-710484, EBI-6169747;
CC       O15169; P39687: ANP32A; NbExp=2; IntAct=EBI-710484, EBI-359234;
CC       O15169; P25054: APC; NbExp=17; IntAct=EBI-710484, EBI-727707;
CC       O15169; P49407: ARRB1; NbExp=2; IntAct=EBI-710484, EBI-743313;
CC       O15169; O15169: AXIN1; NbExp=5; IntAct=EBI-710484, EBI-710484;
CC       O15169; Q13137: CALCOCO2; NbExp=3; IntAct=EBI-710484, EBI-739580;
CC       O15169; Q9H257-2: CARD9; NbExp=3; IntAct=EBI-710484, EBI-11530605;
CC       O15169; Q2TAC2-2: CCDC57; NbExp=3; IntAct=EBI-710484, EBI-10961624;
CC       O15169; Q14194: CRMP1; NbExp=2; IntAct=EBI-710484, EBI-473101;
CC       O15169; P49674: CSNK1E; NbExp=5; IntAct=EBI-710484, EBI-749343;
CC       O15169; P35222: CTNNB1; NbExp=44; IntAct=EBI-710484, EBI-491549;
CC       O15169; Q5VWQ8-2: DAB2IP; NbExp=2; IntAct=EBI-710484, EBI-9543020;
CC       O15169; O14641: DVL2; NbExp=3; IntAct=EBI-710484, EBI-740850;
CC       O15169; Q9UKB1: FBXW11; NbExp=4; IntAct=EBI-710484, EBI-355189;
CC       O15169; Q08379: GOLGA2; NbExp=3; IntAct=EBI-710484, EBI-618309;
CC       O15169; P49840: GSK3A; NbExp=6; IntAct=EBI-710484, EBI-1044067;
CC       O15169; P49841: GSK3B; NbExp=52; IntAct=EBI-710484, EBI-373586;
CC       O15169; P14923: JUP; NbExp=4; IntAct=EBI-710484, EBI-702484;
CC       O15169; Q6A162: KRT40; NbExp=3; IntAct=EBI-710484, EBI-10171697;
CC       O15169; Q9BQ66: KRTAP4-12; NbExp=3; IntAct=EBI-710484, EBI-739863;
CC       O15169; Q9BYR5: KRTAP4-2; NbExp=3; IntAct=EBI-710484, EBI-10172511;
CC       O15169; Q969G2: LHX4; NbExp=3; IntAct=EBI-710484, EBI-2865388;
CC       O15169; Q99750: MDFI; NbExp=3; IntAct=EBI-710484, EBI-724076;
CC       O15169; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-710484, EBI-16439278;
CC       O15169; Q9UJV3-2: MID2; NbExp=3; IntAct=EBI-710484, EBI-10172526;
CC       O15169; Q5JR59-3: MTUS2; NbExp=3; IntAct=EBI-710484, EBI-11522433;
CC       O15169; P01106: MYC; NbExp=10; IntAct=EBI-710484, EBI-447544;
CC       O15169; P35813: PPM1A; NbExp=2; IntAct=EBI-710484, EBI-989143;
CC       O15169; P62136: PPP1CA; NbExp=4; IntAct=EBI-710484, EBI-357253;
CC       O15169; O43586: PSTPIP1; NbExp=3; IntAct=EBI-710484, EBI-1050964;
CC       O15169; Q6ZNA4: RNF111; NbExp=2; IntAct=EBI-710484, EBI-2129175;
CC       O15169; Q96KG9-4: SCYL1; NbExp=3; IntAct=EBI-710484, EBI-12023020;
CC       O15169; O15105: SMAD7; NbExp=8; IntAct=EBI-710484, EBI-3861591;
CC       O15169; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-710484, EBI-5235340;
CC       O15169; O75558: STX11; NbExp=3; IntAct=EBI-710484, EBI-714135;
CC       O15169; P63165: SUMO1; NbExp=3; IntAct=EBI-710484, EBI-80140;
CC       O15169; G2XKQ0: SUMO1P1; NbExp=3; IntAct=EBI-710484, EBI-10175576;
CC       O15169; Q9UBB9: TFIP11; NbExp=3; IntAct=EBI-710484, EBI-1105213;
CC       O15169; Q15583: TGIF1; NbExp=4; IntAct=EBI-710484, EBI-714215;
CC       O15169; Q9H2K2: TNKS2; NbExp=2; IntAct=EBI-710484, EBI-4398527;
CC       O15169; P04637: TP53; NbExp=4; IntAct=EBI-710484, EBI-366083;
CC       O15169; Q12933: TRAF2; NbExp=3; IntAct=EBI-710484, EBI-355744;
CC       O15169; Q9C019: TRIM15; NbExp=3; IntAct=EBI-710484, EBI-2342111;
CC       O15169; P14373: TRIM27; NbExp=3; IntAct=EBI-710484, EBI-719493;
CC       O15169; Q14134: TRIM29; NbExp=2; IntAct=EBI-710484, EBI-702370;
CC       O15169; O94972: TRIM37; NbExp=3; IntAct=EBI-710484, EBI-741602;
CC       O15169; Q15654: TRIP6; NbExp=6; IntAct=EBI-710484, EBI-742327;
CC       O15169; P23258: TUBG1; NbExp=4; IntAct=EBI-710484, EBI-302589;
CC       O15169; Q9H7D7: WDR26; NbExp=4; IntAct=EBI-710484, EBI-1046864;
CC       O15169; P46937: YAP1; NbExp=11; IntAct=EBI-710484, EBI-1044059;
CC       O15169; Q9HCK0: ZBTB26; NbExp=3; IntAct=EBI-710484, EBI-3918996;
CC       O15169; Q96K21-3: ZFYVE19; NbExp=3; IntAct=EBI-710484, EBI-10187928;
CC       O15169; P70039: apc; Xeno; NbExp=2; IntAct=EBI-710484, EBI-8069633;
CC       O15169; Q02248: Ctnnb1; Xeno; NbExp=5; IntAct=EBI-710484, EBI-397872;
CC       O15169; G1T8E2: GSK3B; Xeno; NbExp=2; IntAct=EBI-710484, EBI-3833365;
CC       O15169; Q99ML9: Rnf111; Xeno; NbExp=5; IntAct=EBI-710484, EBI-646015;
CC       O15169-2; O75581: LRP6; NbExp=3; IntAct=EBI-10987526, EBI-910915;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16601693}. Nucleus
CC       {ECO:0000269|PubMed:17210684}. Membrane {ECO:0000250|UniProtKB:O35625}.
CC       Cell membrane {ECO:0000250|UniProtKB:O35625}. Note=MACF1 is required
CC       for its translocation to cell membrane (By similarity). On UV
CC       irradiation, translocates to the nucleus and colocalizes with DAAX
CC       (PubMed:17210684). {ECO:0000250|UniProtKB:O35625,
CC       ECO:0000269|PubMed:17210684}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O15169-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15169-2; Sequence=VSP_019398;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed.
CC   -!- DOMAIN: The tankyrase-binding motif (also named TBD) is required for
CC       interaction with tankyrase TNKS and TNKS2.
CC       {ECO:0000269|PubMed:19759537}.
CC   -!- PTM: Phosphorylation and dephosphorylation of AXIN1 regulates assembly
CC       and function of the beta-catenin complex. Phosphorylated by CK1 and
CC       GSK3B. Dephosphorylated by PPP1CA and PPP2CA. Phosphorylation by CK1
CC       enhances binding of GSK3B to AXIN1. {ECO:0000269|PubMed:17318175,
CC       ECO:0000269|PubMed:9920888}.
CC   -!- PTM: ADP-ribosylated by tankyrase TNKS and TNKS2. Poly-ADP-ribosylated
CC       protein is recognized by RNF146, followed by ubiquitination at 'Lys-48'
CC       and subsequent activation of the Wnt signaling pathway.
CC       {ECO:0000269|PubMed:21383061}.
CC   -!- PTM: Ubiquitinated by RNF146 when poly-ADP-ribosylated, leading to its
CC       degradation and subsequent activation of the Wnt signaling pathway.
CC       Sumoylation at Lys-857 and Lys-860 prevents ubiquitination and
CC       degradation. Sumoylation is required for AXIN1-mediated JNK activation.
CC       Deubiquitinated by USP34, deubiquitinated downstream of beta-catenin
CC       stabilization step: deubiquitination is important for nuclear
CC       accumulation during Wnt signaling to positively regulate beta-catenin
CC       (CTNBB1)-mediated transcription. Ubiquitination by SIAH1 and SIAH2
CC       induces its proteasomal degradation as part of the activation of the
CC       Wnt signaling pathway (PubMed:28546513). {ECO:0000269|PubMed:18632848,
CC       ECO:0000269|PubMed:21383061, ECO:0000269|PubMed:28546513}.
CC   -!- DISEASE: Hepatocellular carcinoma (HCC) [MIM:114550]: A primary
CC       malignant neoplasm of epithelial liver cells. The major risk factors
CC       for HCC are chronic hepatitis B virus (HBV) infection, chronic
CC       hepatitis C virus (HCV) infection, prolonged dietary aflatoxin
CC       exposure, alcoholic cirrhosis, and cirrhosis due to other causes.
CC       {ECO:0000269|PubMed:12101426}. Note=The gene represented in this entry
CC       is involved in disease pathogenesis.
CC   -!- DISEASE: Caudal duplication anomaly (CADUA) [MIM:607864]: A condition
CC       characterized by the occurrence of duplications of different organs in
CC       the caudal region. {ECO:0000269|PubMed:16773576}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry. Caudal
CC       duplication anomaly is associated with hypermethylation of the AXIN1
CC       promoter.
CC   -!- DISEASE: Craniometadiaphyseal osteosclerosis with hip dysplasia (CMDOH)
CC       [MIM:620558]: An autosomal recessive skeletal dysplasia characterized
CC       by macrocephaly, cranial hyperostosis, and vertebral endplate
CC       sclerosis. Other frequent findings include hip dysplasia, heart
CC       malformations, variable developmental delay, and hematological
CC       anomalies. Bone biopsy shows evidence of increased osteoblast and
CC       reduced osteoclast function at the growth plate resorption zone,
CC       leading to coarse trabeculae. {ECO:0000269|PubMed:37582359}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC51624.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/379/AXIN1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF009674; AAC51624.1; ALT_INIT; mRNA.
DR   EMBL; AE006463; AAK61224.1; -; Genomic_DNA.
DR   EMBL; Z69667; CAI95589.2; -; Genomic_DNA.
DR   EMBL; AC005202; CAI95589.2; JOINED; Genomic_DNA.
DR   EMBL; Z99754; CAI95589.2; JOINED; Genomic_DNA.
DR   EMBL; Z69667; CAI95590.2; -; Genomic_DNA.
DR   EMBL; AC005202; CAI95590.2; JOINED; Genomic_DNA.
DR   EMBL; Z99754; CAI95590.2; JOINED; Genomic_DNA.
DR   EMBL; Z99754; CAI95600.2; -; Genomic_DNA.
DR   EMBL; AC005202; CAI95600.2; JOINED; Genomic_DNA.
DR   EMBL; Z69667; CAI95600.2; JOINED; Genomic_DNA.
DR   EMBL; Z99754; CAI95601.2; -; Genomic_DNA.
DR   EMBL; AC005202; CAI95601.2; JOINED; Genomic_DNA.
DR   EMBL; Z69667; CAI95601.2; JOINED; Genomic_DNA.
DR   EMBL; BC017447; AAH17447.1; -; mRNA.
DR   EMBL; BC044648; AAH44648.1; -; mRNA.
DR   CCDS; CCDS10405.1; -. [O15169-1]
DR   CCDS; CCDS10406.1; -. [O15169-2]
DR   RefSeq; NP_003493.1; NM_003502.4. [O15169-1]
DR   RefSeq; NP_851393.1; NM_181050.3. [O15169-2]
DR   PDB; 1DK8; X-ray; 1.57 A; A=74-220.
DR   PDB; 1EMU; X-ray; 1.90 A; A=80-211.
DR   PDB; 1O9U; X-ray; 2.40 A; B=383-400.
DR   PDB; 3ZDI; X-ray; 2.64 A; B=383-400.
DR   PDB; 4B7T; X-ray; 2.77 A; B=383-400.
DR   PDB; 4NM0; X-ray; 2.50 A; B=383-402.
DR   PDB; 4NM3; X-ray; 2.10 A; B=383-402.
DR   PDB; 4NM5; X-ray; 2.30 A; B=383-402.
DR   PDB; 4NM7; X-ray; 2.30 A; B=383-402.
DR   PDB; 4NU1; X-ray; 2.50 A; B=383-402.
DR   PDB; 5WZZ; X-ray; 2.10 A; E/F/G/H=375-394.
DR   PDB; 6JCK; X-ray; 3.09 A; A=781-862.
DR   PDB; 7SXF; X-ray; 1.94 A; B=385-399.
DR   PDB; 7SXG; X-ray; 2.40 A; B=385-400.
DR   PDB; 7SXH; X-ray; 2.09 A; B=385-400.
DR   PDB; 7SXJ; X-ray; 1.85 A; B=384-400.
DR   PDB; 7Y1P; X-ray; 2.60 A; A/B/C/D=74-220.
DR   PDB; 8RU3; X-ray; 2.00 A; P=468-479.
DR   PDB; 8RU4; X-ray; 2.13 A; C=469-479.
DR   PDB; 8VMG; X-ray; 2.45 A; C/D=383-435.
DR   PDBsum; 1DK8; -.
DR   PDBsum; 1EMU; -.
DR   PDBsum; 1O9U; -.
DR   PDBsum; 3ZDI; -.
DR   PDBsum; 4B7T; -.
DR   PDBsum; 4NM0; -.
DR   PDBsum; 4NM3; -.
DR   PDBsum; 4NM5; -.
DR   PDBsum; 4NM7; -.
DR   PDBsum; 4NU1; -.
DR   PDBsum; 5WZZ; -.
DR   PDBsum; 6JCK; -.
DR   PDBsum; 7SXF; -.
DR   PDBsum; 7SXG; -.
DR   PDBsum; 7SXH; -.
DR   PDBsum; 7SXJ; -.
DR   PDBsum; 7Y1P; -.
DR   PDBsum; 8RU3; -.
DR   PDBsum; 8RU4; -.
DR   PDBsum; 8VMG; -.
DR   AlphaFoldDB; O15169; -.
DR   SMR; O15169; -.
DR   BioGRID; 113909; 153.
DR   ComplexPortal; CPX-107; Beta-catenin destruction core complex, APC-AXIN1-GSK3A variant.
DR   ComplexPortal; CPX-109; Beta-catenin destruction core complex, APC-AXIN1-GSK3B variant.
DR   ComplexPortal; CPX-442; Beta-catenin destruction core complex, APC2-AXIN1-GSK3A variant.
DR   ComplexPortal; CPX-99; Beta-catenin destruction core complex, APC2-AXIN1-GSK3B variant.
DR   CORUM; O15169; -.
DR   DIP; DIP-34630N; -.
DR   FunCoup; O15169; 2413.
DR   IntAct; O15169; 134.
DR   MINT; O15169; -.
DR   STRING; 9606.ENSP00000262320; -.
DR   ChEMBL; CHEMBL1255127; -.
DR   DrugBank; DB04447; 1,4-Dithiothreitol.
DR   GlyGen; O15169; 1 site.
DR   iPTMnet; O15169; -.
DR   PhosphoSitePlus; O15169; -.
DR   BioMuta; AXIN1; -.
DR   jPOST; O15169; -.
DR   MassIVE; O15169; -.
DR   PaxDb; 9606-ENSP00000262320; -.
DR   PeptideAtlas; O15169; -.
DR   ProteomicsDB; 48492; -. [O15169-1]
DR   ProteomicsDB; 48493; -. [O15169-2]
DR   Pumba; O15169; -.
DR   Antibodypedia; 22635; 542 antibodies from 40 providers.
DR   DNASU; 8312; -.
DR   Ensembl; ENST00000262320.8; ENSP00000262320.3; ENSG00000103126.15. [O15169-1]
DR   Ensembl; ENST00000354866.7; ENSP00000346935.3; ENSG00000103126.15. [O15169-2]
DR   GeneID; 8312; -.
DR   KEGG; hsa:8312; -.
DR   MANE-Select; ENST00000262320.8; ENSP00000262320.3; NM_003502.4; NP_003493.1.
DR   UCSC; uc002cgp.3; human. [O15169-1]
DR   AGR; HGNC:903; -.
DR   CTD; 8312; -.
DR   DisGeNET; 8312; -.
DR   GeneCards; AXIN1; -.
DR   HGNC; HGNC:903; AXIN1.
DR   HPA; ENSG00000103126; Low tissue specificity.
DR   MalaCards; AXIN1; -.
DR   MIM; 114550; phenotype.
DR   MIM; 603816; gene.
DR   MIM; 607864; phenotype.
DR   MIM; 620558; phenotype.
DR   OpenTargets; ENSG00000103126; -.
DR   Orphanet; 210159; Adult hepatocellular carcinoma.
DR   VEuPathDB; HostDB:ENSG00000103126; -.
DR   eggNOG; KOG3589; Eukaryota.
DR   GeneTree; ENSGT00940000156947; -.
DR   HOGENOM; CLU_016422_0_0_1; -.
DR   InParanoid; O15169; -.
DR   OMA; YVYTAST; -.
DR   OrthoDB; 10007451at2759; -.
DR   PAN-GO; O15169; 13 GO annotations based on evolutionary models.
DR   PhylomeDB; O15169; -.
DR   PathwayCommons; O15169; -.
DR   Reactome; R-HSA-195253; Degradation of beta-catenin by the destruction complex.
DR   Reactome; R-HSA-196299; Beta-catenin phosphorylation cascade.
DR   Reactome; R-HSA-201681; TCF dependent signaling in response to WNT.
DR   Reactome; R-HSA-4641257; Degradation of AXIN.
DR   Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   Reactome; R-HSA-5339716; Signaling by GSK3beta mutants.
DR   Reactome; R-HSA-5358747; CTNNB1 S33 mutants aren't phosphorylated.
DR   Reactome; R-HSA-5358749; CTNNB1 S37 mutants aren't phosphorylated.
DR   Reactome; R-HSA-5358751; CTNNB1 S45 mutants aren't phosphorylated.
DR   Reactome; R-HSA-5358752; CTNNB1 T41 mutants aren't phosphorylated.
DR   Reactome; R-HSA-5467337; APC truncation mutants have impaired AXIN binding.
DR   Reactome; R-HSA-5467340; AXIN missense mutants destabilize the destruction complex.
DR   Reactome; R-HSA-5467348; Truncations of AMER1 destabilize the destruction complex.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-8931987; RUNX1 regulates estrogen receptor mediated transcription.
DR   Reactome; R-HSA-8939256; RUNX1 regulates transcription of genes involved in WNT signaling.
DR   Reactome; R-HSA-9018519; Estrogen-dependent gene expression.
DR   SignaLink; O15169; -.
DR   SIGNOR; O15169; -.
DR   BioGRID-ORCS; 8312; 42 hits in 1179 CRISPR screens.
DR   CD-CODE; D8D47D1F; Synthetic Condensate 000297.
DR   ChiTaRS; AXIN1; human.
DR   EvolutionaryTrace; O15169; -.
DR   GeneWiki; AXIN1; -.
DR   GenomeRNAi; 8312; -.
DR   Pharos; O15169; Tbio.
DR   PRO; PR:O15169; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; O15169; protein.
DR   Bgee; ENSG00000103126; Expressed in granulocyte and 102 other cell types or tissues.
DR   ExpressionAtlas; O15169; baseline and differential.
DR   GO; GO:0030877; C:beta-catenin destruction complex; IDA:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IEA:Ensembl.
DR   GO; GO:0071944; C:cell periphery; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; ISS:BHF-UCL.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016328; C:lateral plasma membrane; IDA:MGI.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:1990909; C:Wnt signalosome; IEA:Ensembl.
DR   GO; GO:0070016; F:armadillo repeat domain binding; ISS:BHF-UCL.
DR   GO; GO:0008013; F:beta-catenin binding; IDA:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0070411; F:I-SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0060090; F:molecular adaptor activity; IDA:BHF-UCL.
DR   GO; GO:0002039; F:p53 binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; ISS:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; ISS:BHF-UCL.
DR   GO; GO:0043539; F:protein serine/threonine kinase activator activity; IDA:BHF-UCL.
DR   GO; GO:0120283; F:protein serine/threonine kinase binding; IPI:BHF-UCL.
DR   GO; GO:0070412; F:R-SMAD binding; IEA:Ensembl.
DR   GO; GO:0035591; F:signaling adaptor activity; TAS:BHF-UCL.
DR   GO; GO:0046332; F:SMAD binding; IPI:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:1990756; F:ubiquitin-like ligase-substrate adaptor activity; IMP:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0048320; P:axial mesoderm formation; IEA:Ensembl.
DR   GO; GO:1904885; P:beta-catenin destruction complex assembly; IDA:BHF-UCL.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0048468; P:cell development; IBA:GO_Central.
DR   GO; GO:0031122; P:cytoplasmic microtubule organization; IEA:Ensembl.
DR   GO; GO:0009950; P:dorsal/ventral axis specification; IEA:Ensembl.
DR   GO; GO:0044725; P:epigenetic programming in the zygotic pronuclei; IEA:Ensembl.
DR   GO; GO:0060322; P:head development; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0045599; P:negative regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0051248; P:negative regulation of protein metabolic process; IEA:Ensembl.
DR   GO; GO:0034244; P:negative regulation of transcription elongation by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0006913; P:nucleocytoplasmic transport; IEA:Ensembl.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; ISS:UniProtKB.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:BHF-UCL.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IMP:BHF-UCL.
DR   GO; GO:0030511; P:positive regulation of transforming growth factor beta receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:2000060; P:positive regulation of ubiquitin-dependent protein catabolic process; ISS:BHF-UCL.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; NAS:ComplexPortal.
DR   GO; GO:0000209; P:protein polyubiquitination; IEA:Ensembl.
DR   GO; GO:0065003; P:protein-containing complex assembly; IDA:BHF-UCL.
DR   GO; GO:0007605; P:sensory perception of sound; IEA:Ensembl.
DR   CDD; cd11582; Axin_TNKS_binding; 1.
DR   CDD; cd08707; RGS_Axin; 1.
DR   DisProt; DP00959; -.
DR   FunFam; 1.10.167.10:FF:000003; Axin 1; 1.
DR   FunFam; 1.10.196.10:FF:000002; Axin 1; 1.
DR   FunFam; 2.40.240.130:FF:000002; Axin 1; 1.
DR   Gene3D; 1.10.196.10; -; 2.
DR   Gene3D; 2.40.240.130; -; 1.
DR   Gene3D; 1.10.167.10; Regulator of G-protein Signalling 4, domain 2; 1.
DR   IDEAL; IID00007; -.
DR   InterPro; IPR043581; Axin-like.
DR   InterPro; IPR014936; Axin_b-cat-bd.
DR   InterPro; IPR032101; Axin_TNKS-bd.
DR   InterPro; IPR001158; DIX.
DR   InterPro; IPR038207; DIX_dom_sf.
DR   InterPro; IPR016137; RGS.
DR   InterPro; IPR036305; RGS_sf.
DR   InterPro; IPR024066; RGS_subdom1/3.
DR   InterPro; IPR044926; RGS_subdomain_2.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   PANTHER; PTHR46102; AXIN; 1.
DR   PANTHER; PTHR46102:SF3; AXIN-1; 1.
DR   Pfam; PF16646; AXIN1_TNKS_BD; 1.
DR   Pfam; PF08833; Axin_b-cat_bind; 1.
DR   Pfam; PF00778; DIX; 1.
DR   Pfam; PF00615; RGS; 1.
DR   PRINTS; PR01301; RGSPROTEIN.
DR   SMART; SM00021; DAX; 1.
DR   SMART; SM00315; RGS; 1.
DR   SUPFAM; SSF48097; Regulator of G-protein signaling, RGS; 1.
DR   SUPFAM; SSF54236; Ubiquitin-like; 1.
DR   PROSITE; PS50841; DIX; 1.
DR   PROSITE; PS50132; RGS; 1.
DR   neXtProt; NX_O15169; -.
DR   PharmGKB; PA25195; -.
DR   TreeFam; TF315454; -.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Alternative splicing; Apoptosis;
KW   Cell membrane; Cytoplasm; Developmental protein; Disease variant;
KW   Isopeptide bond; Membrane; Nucleus; Phosphoprotein;
KW   Proteomics identification; Reference proteome; Tumor suppressor;
KW   Ubl conjugation; Wnt signaling pathway.
FT   CHAIN           1..862
FT                   /note="Axin-1"
FT                   /id="PRO_0000220888"
FT   DOMAIN          88..211
FT                   /note="RGS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00171"
FT   DOMAIN          780..862
FT                   /note="DIX"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00069"
FT   REGION          1..78
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          209..338
FT                   /note="Interaction with TP53"
FT                   /evidence="ECO:0000250"
FT   REGION          215..289
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          316..344
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          348..433
FT                   /note="Interaction with GSK3B"
FT                   /evidence="ECO:0000250|UniProtKB:O70239"
FT   REGION          353..411
FT                   /note="Interaction with SIAH1 and SIAH2"
FT                   /evidence="ECO:0000269|PubMed:28546513"
FT   REGION          413..441
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          434..502
FT                   /note="Interaction with CTNNB1"
FT                   /evidence="ECO:0000250"
FT   REGION          480..500
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          507..757
FT                   /note="Interaction with RNF111"
FT                   /evidence="ECO:0000269|PubMed:16601693"
FT   REGION          531..629
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          575..789
FT                   /note="Interaction with PPP2CA"
FT                   /evidence="ECO:0000269|PubMed:9920888"
FT   REGION          641..679
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          677..752
FT                   /note="Interaction with HIPK2"
FT                   /evidence="ECO:0000250"
FT   MOTIF           20..29
FT                   /note="Tankyrase-binding motif"
FT   COMPBIAS        242..258
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        325..339
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        429..441
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        531..544
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        545..556
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         75
FT                   /note="Phosphoserine; by CK1"
FT                   /evidence="ECO:0000269|PubMed:17318175"
FT   MOD_RES         77
FT                   /note="Phosphoserine; by CK1"
FT                   /evidence="ECO:0000269|PubMed:17318175,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         217
FT                   /note="Phosphoserine; by CK1"
FT                   /evidence="ECO:0000269|PubMed:17318175"
FT   MOD_RES         469
FT                   /note="Phosphoserine; by CK1"
FT                   /evidence="ECO:0000269|PubMed:17318175"
FT   MOD_RES         481
FT                   /note="Phosphothreonine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:O35625"
FT   MOD_RES         486
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         493
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O35625"
FT   MOD_RES         511
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         581
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   CROSSLNK        857
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        860
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         730..765
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_019398"
FT   VARIANT         106
FT                   /note="L -> R (in HCC; uncertain significance; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:12101426"
FT                   /id="VAR_015589"
FT   VARIANT         345
FT                   /note="P -> L (in HCC; uncertain significance; somatic
FT                   mutation; dbSNP:rs779951904)"
FT                   /evidence="ECO:0000269|PubMed:12101426"
FT                   /id="VAR_015590"
FT   VARIANT         425
FT                   /note="G -> S (in HCC; uncertain significance; somatic
FT                   mutation; dbSNP:rs116350678)"
FT                   /evidence="ECO:0000269|PubMed:12101426"
FT                   /id="VAR_015591"
FT   VARIANT         650
FT                   /note="G -> S (in dbSNP:rs117208012)"
FT                   /evidence="ECO:0000269|PubMed:12101426"
FT                   /id="VAR_015592"
FT   VARIANT         723..862
FT                   /note="Missing (in CMDOH; likely pathogenic; loss of
FT                   negative regulation of canonical Wnt signaling pathway;
FT                   results in enhanced basal Wnt signaling in primary
FT                   homozygous patient-derived fibroblasts and in genome-edited
FT                   cells; the mutant protein is expressed at low levels in
FT                   primary homozygous patient-derived fibroblasts)"
FT                   /evidence="ECO:0000269|PubMed:37582359"
FT                   /id="VAR_089057"
FT   VARIANT         841..862
FT                   /note="Missing (in CMDOH; uncertain significance)"
FT                   /evidence="ECO:0000269|PubMed:37582359"
FT                   /id="VAR_089058"
FT   VARIANT         841
FT                   /note="R -> Q (in dbSNP:rs34015754)"
FT                   /evidence="ECO:0000269|PubMed:12101426"
FT                   /id="VAR_015593"
FT   MUTAGEN         383
FT                   /note="V->A: Loss of interaction with SIAH1. Decreased
FT                   SIAH1-induced proteasome-mediated ubiquitin-dependent
FT                   degradation of AXIN1. No effect on interaction with GSK3B."
FT                   /evidence="ECO:0000269|PubMed:28546513"
FT   MUTAGEN         385
FT                   /note="P->A: Loss of interaction with SIAH1. Decreased
FT                   SIAH1-induced proteasome-mediated ubiquitin-dependent
FT                   degradation of AXIN1. No effect on interaction with GSK3B."
FT                   /evidence="ECO:0000269|PubMed:28546513"
FT   CONFLICT        360
FT                   /note="V -> A (in Ref. 1; AAC51624)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        451..455
FT                   /note="CVDMG -> LCWTWA (in Ref. 1; AAC51624)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        482
FT                   /note="P -> T (in Ref. 1; AAC51624)"
FT                   /evidence="ECO:0000305"
FT   HELIX           81..87
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   HELIX           89..92
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   HELIX           96..107
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   TURN            108..110
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   HELIX           112..126
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   HELIX           131..133
FT                   /evidence="ECO:0007829|PDB:1EMU"
FT   HELIX           134..148
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   HELIX           155..159
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   HELIX           162..174
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   TURN            179..182
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   HELIX           183..195
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   HELIX           197..201
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   HELIX           205..208
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   TURN            209..212
FT                   /evidence="ECO:0007829|PDB:1DK8"
FT   STRAND          379..383
FT                   /evidence="ECO:0007829|PDB:5WZZ"
FT   HELIX           385..397
FT                   /evidence="ECO:0007829|PDB:7SXJ"
FT   HELIX           469..478
FT                   /evidence="ECO:0007829|PDB:8RU3"
FT   STRAND          782..786
FT                   /evidence="ECO:0007829|PDB:6JCK"
FT   STRAND          798..801
FT                   /evidence="ECO:0007829|PDB:6JCK"
FT   HELIX           807..811
FT                   /evidence="ECO:0007829|PDB:6JCK"
FT   STRAND          818..826
FT                   /evidence="ECO:0007829|PDB:6JCK"
FT   STRAND          836..839
FT                   /evidence="ECO:0007829|PDB:6JCK"
FT   STRAND          853..860
FT                   /evidence="ECO:0007829|PDB:6JCK"
SQ   SEQUENCE   862 AA;  95635 MW;  10779173F5092F3F CRC64;
     MNIQEQGFPL DLGASFTEDA PRPPVPGEEG ELVSTDPRPA SYSFCSGKGV GIKGETSTAT
     PRRSDLDLGY EPEGSASPTP PYLKWAESLH SLLDDQDGIS LFRTFLKQEG CADLLDFWFA
     CTGFRKLEPC DSNEEKRLKL ARAIYRKYIL DNNGIVSRQT KPATKSFIKG CIMKQLIDPA
     MFDQAQTEIQ ATMEENTYPS FLKSDIYLEY TRTGSESPKV CSDQSSGSGT GKGISGYLPT
     LNEDEEWKCD QDMDEDDGRD AAPPGRLPQK LLLETAAPRV SSSRRYSEGR EFRYGSWREP
     VNPYYVNAGY ALAPATSAND SEQQSLSSDA DTLSLTDSSV DGIPPYRIRK QHRREMQESV
     QVNGRVPLPH IPRTYRVPKE VRVEPQKFAE ELIHRLEAVQ RTREAEEKLE ERLKRVRMEE
     EGEDGDPSSG PPGPCHKLPP APAWHHFPPR CVDMGCAGLR DAHEENPESI LDEHVQRVLR
     TPGRQSPGPG HRSPDSGHVA KMPVALGGAA SGHGKHVPKS GAKLDAAGLH HHRHVHHHVH
     HSTARPKEQV EAEATRRAQS SFAWGLEPHS HGARSRGYSE SVGAAPNASD GLAHSGKVGV
     ACKRNAKKAE SGKSASTEVP GASEDAEKNQ KIMQWIIEGE KEISRHRRTG HGSSGTRKPQ
     PHENSRPLSL EHPWAGPQLR TSVQPSHLFI QDPTMPPHPA PNPLTQLEEA RRRLEEEEKR
     ASRAPSKQRY VQEVMRRGRA CVRPACAPVL HVVPAVSDME LSETETRSQR KVGGGSAQPC
     DSIVVAYYFC GEPIPYRTLV RGRAVTLGQF KELLTKKGSY RYYFKKVSDE FDCGVVFEEV
     REDEAVLPVF EEKIIGKVEK VD
//
